Domvanalimab
Gestational Trophoblastic Neoplasm
Explore 6 assets in Gestational Trophoblastic Neoplasm →Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
Hospices Civils de Lyon
Modality
UNKNOWN
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06790706CT.gov IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE Cancers | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Gestational Trophoblastic Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Domvanalimab (this asset) | Hospices Civils de Lyon | P2 | CCC · 53 |
| Amifostine | Gynecologic Oncology Group | P3 | B |
| Nivestim | Fred Hutchinson Cancer Center | P2 | B |
| Alemtuzumab | Fred Hutchinson Cancer Center | P2 | B |
| Moxifloxacin | OHSU Knight Cancer Institute | P3 | B |
| Prednisone | Fred Hutchinson Cancer Center | P2 | B |
| Alpha-Interferon | Cancer Treatment Centers of America | P2 | B |
| Tacrolimus | Case Comprehensive Cancer Center | P2 | B |
| Ondansetron | Fred Hutchinson Cancer Center | P2 | B |
+17 more in the Gestational Trophoblastic Neoplasm cohort
Other indications for Domvanalimab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Non-Small Cell Squamous Lung Carcinoma | — | P2 | B · 57 |
| Non-Small Cell Lung Carcinoma | — | P3 | B · 56 |
| Carcinoid Tumor | — | P2 | CCC · 53 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Domvanalimab in Gestational Trophoblastic Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/domvanalimab-gestational-trophoblastic-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →